Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kah-Whye Peng

Showing results (71-80 of 116) with videos related to

Pageof 12
Sort By:
Blood|August 12, 2009
Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectorsCecilia Frecha, Caroline Costa, Camille Lévy, et al.
Expert Opinion on Biological Therapy|January 16, 2008
Oncolytic measles virus strains in the treatment of gliomasCory Allen, Georgia Paraskevakou, Chunsheng Liu, et al.
Human Gene Therapy. Clinical Development|November 14, 2013
Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogsAmy K LeBlanc, Shruthi Naik, Gina D Galyon, et al.
Human Gene Therapy|October 28, 2003
Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic miceKah-Whye Peng, Marie Frenzke, Rae Myers, et al.
Journal of Materials Science. Materials in Medicine|March 25, 2008
Controlled size and morphology of EDTMP-doped hydroxyapatite nanoparticles as model for 153Samarium-EDTMP dopingYuling Jamie Han, Say Chye Joachim Loo, Ngoc Thao Phung, et al.
Leukemia|April 25, 2020
Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myelomaNandakumar Packiriswamy, Deepak Upreti, Yumei Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy modelEmily K Mader, Yoshihiro Maeyama, Yi Lin, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 28, 2016
Robust Oncolytic Virotherapy Induces Tumor Lysis Syndrome and Associated Toxicities in the MPC-11 Plasmacytoma ModelLianwen Zhang, Michael B Steele, Nathan Jenks, et al.
Biochemical and Biophysical Research Communications|September 21, 2005
Interaction of measles virus vectors with Auger electron emitting radioisotopesDavid Dingli, Kah-Whye Peng, Mary E Harvey, et al.
Human Gene Therapy. Clinical Development|August 18, 2016
Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NISLianwen Zhang, Michael B Steele, Nathan Jenks, et al.
Pageof 12

Showing results (71-80 of 116) with videos related to

Sort By:
Pageof 12
Blood|August 12, 2009
Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectorsCecilia Frecha, Caroline Costa, Camille Lévy, et al.
Expert Opinion on Biological Therapy|January 16, 2008
Oncolytic measles virus strains in the treatment of gliomasCory Allen, Georgia Paraskevakou, Chunsheng Liu, et al.
Human Gene Therapy. Clinical Development|November 14, 2013
Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogsAmy K LeBlanc, Shruthi Naik, Gina D Galyon, et al.
Human Gene Therapy|October 28, 2003
Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic miceKah-Whye Peng, Marie Frenzke, Rae Myers, et al.
Journal of Materials Science. Materials in Medicine|March 25, 2008
Controlled size and morphology of EDTMP-doped hydroxyapatite nanoparticles as model for 153Samarium-EDTMP dopingYuling Jamie Han, Say Chye Joachim Loo, Ngoc Thao Phung, et al.
Leukemia|April 25, 2020
Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myelomaNandakumar Packiriswamy, Deepak Upreti, Yumei Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy modelEmily K Mader, Yoshihiro Maeyama, Yi Lin, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 28, 2016
Robust Oncolytic Virotherapy Induces Tumor Lysis Syndrome and Associated Toxicities in the MPC-11 Plasmacytoma ModelLianwen Zhang, Michael B Steele, Nathan Jenks, et al.
Biochemical and Biophysical Research Communications|September 21, 2005
Interaction of measles virus vectors with Auger electron emitting radioisotopesDavid Dingli, Kah-Whye Peng, Mary E Harvey, et al.
Human Gene Therapy. Clinical Development|August 18, 2016
Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NISLianwen Zhang, Michael B Steele, Nathan Jenks, et al.
Pageof 12